The live and archived webcasts of the company presentations will be accessible from the company's website at http://ir.ultragenyx.com/events.cfm . The replays of the webcasts will be available for 90 days. About Ultragenyx Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/ultragenyx-present-upcoming-investor-conferences-130000847.html
Ebola: Give Africans the drug Americans used (Opinion) - CNN.com
Some reports indicate they received ZMapp under the FDA's "compassionate use" rule, which permits untested drugs to be given to consenting patients who might otherwise die. This is a triumph of common sense and compassion over bureaucratic red tape. Harriet A. Washington One of the chief concerns about using unapproved medications is that we don't know what the risks are: The drug may not work, it may work with serious adverse effects, or it may prove as deadly as the disease. But as a doctor, Brantly understood the risks, and like him, Writebol had no other options.
For the original version including any supplementary images or video, visit http://www.cnn.com/2014/08/06/opinion/washington-ebola-zmapp-drug-africa/index.html
Mallinckrodt plc Reports Fiscal 2014 Third Quarter Financial Results; Updates Full-Year 2014 Guidance, Increasing Net Sales and Adjusted Diluted Earnings Per Share - Yahoo Finance
To learn more about Mallinckrodt, visit www.mallinckrodt.com . (1)NON-GAAP FINANCIAL MEASURES This press release contains financial measures, including adjusted net income, adjusted diluted earnings per share, adjusted gross profit, operational growth and effective tax rate, which are considered "non-GAAP" financial measures under applicable Securities and Exchange Commission rules and regulations. Adjusted net income represents net income, prepared in accordance with accounting principles generally accepted in the U.S. (GAAP), excluding the after-tax effects related to separation costs; restructuring and related charges, net; amortization; discontinued operations; and other items identified by the company. Adjusted diluted earnings per share represents adjusted net income divided by the number of diluted shares. The non-GAAP effective tax rate reflects the tax impact of adjustments between net income and adjusted net income and certain effects associated with acquisitions. Adjusted gross profit represents gross profit, prepared in accordance with GAAP, excluding amortization and inventory step-up expense. Operational growth measures the change in net sales between current- and prior-year periods using a constant currency, the exchange rate in effect during the applicable prior-year period.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/mallinckrodt-plc-reports-fiscal-2014-110000179.html